Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
NRG Oncology
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)
University of California, San Diego
Centre Leon Berard
Celldex Therapeutics
University of Texas Southwestern Medical Center
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
National Institutes of Health Clinical Center (CC)
Icahn School of Medicine at Mount Sinai
Azienda USL 4 Prato
University of Zurich
University of Michigan Rogel Cancer Center
University of Leipzig
Groupe Oncologie Radiotherapie Tete et Cou